Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Drops By 56.0%

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 5,100 shares, a drop of 56.0% from the October 31st total of 11,600 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 933,200 shares, the short-interest ratio is currently 0.0 days.

Pasithea Therapeutics Trading Down 3.7 %

Shares of KTTA traded down $0.11 during trading hours on Thursday, hitting $2.90. 23,375 shares of the stock traded hands, compared to its average volume of 280,277. The business has a fifty day moving average of $4.07 and a 200-day moving average of $4.84. Pasithea Therapeutics has a 1-year low of $2.87 and a 1-year high of $17.40.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.